EUVIMEDEUVIMED entdecken
Crossref

Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology

Murad Alturkustani iD, Adam D Walker, Everardo A Castañeda, Jennifer A Cotter iD

Journal of Neuropathology & Experimental Neurology · 2024

DOI: 10.1093/jnen/nlae082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2024. Verfasst von Murad Alturkustani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Oligodendrocyte Transcription Factor 2, Brain Neoplasms, Glioma, Immunohistochemistry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluates the diagnostic utility of OLIG2 immunohistochemistry for distinguishing between pediatric high-grade gliomas (pHGG) and embryonal tumors (ETs) of the CNS. Utilizing a retrospective pediatric cohort (1990-2021) of 56 CNS tumors, classified initially as primitive neuroectodermal tumors or CNS ET, we reclassified the cases based on WHO CNS5 criteria after comprehensive review and additional molecular testing that included next-generation sequencing and DNA methylation profiling. Our results indicate that OLIG2 immunopositivity was negative or minimal in a significant subset of pHGG cases (6 out of 11). At the same time, it showed diffuse expression in all cases of CNS neuroblastomas with FOXR2 activation (5/5), demonstrating its limited specificity in differentiating between pHGG and ET. Variable OLIG2 expression in other ETs, ATRT, and ETMR suggests the broader diagnostic implications of the marker. Furthermore, incidental findings of OLIG2 positivity in cases traditionally expected to be negative, such as medulloblastoma and ependymoma, introduce an additional layer of complexity. Together, these findings highlight the challenges of relying solely on OLIG2 immunostaining for accurate tumor classification in pediatric CNS neoplasms and underscore the importance of an integrated diagnostic approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligodendrocyte Transcription Factor 2Brain NeoplasmsGliomaImmunohistochemistryHumansChildMaleChild, PreschoolFemaleInfantRetrospective StudiesAdolescentNeoplasms, Germ Cell and EmbryonalBiomarkers, TumorCohort Studies

Stichwörter der Autor:innen

CNS neuroblastoma with FOXR2 activationOLIG2embryonal tumorshigh-grade pediatric glioma

Substanzen

Oligodendrocyte Transcription Factor 2OLIG2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, United States.
  • Department of Pathology, University of Western Ontario, London, ON, Canada.
  • Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

ORCID-Profile: Murad Alturkustani, Jennifer A Cotter

Zitieren

APA

Alturkustani, M., Walker, A. D., Castañeda, E. A., & Cotter, J. A. (2024). Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae082

Vancouver

Alturkustani M, Walker AD, Castañeda EA, Cotter JA. Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology. Journal of Neuropathology & Experimental Neurology. 2024. doi:10.1093/jnen/nlae082

BibTeX
@article{Alturkustani2024,
  author = {Alturkustani, Murad and Walker, Adam D and Castañeda, Everardo A and Cotter, Jennifer A},
  title = {Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2024},
  doi = {10.1093/jnen/nlae082}
}
Kostenlos starten →